Literature DB >> 29279027

Harnessing mutual exclusivity between TP53 and ARID1 A mutations.

Shuai Wu1, Nail Fatkhutdinov1,2, Rugang Zhang1.   

Abstract

Entities:  

Keywords:  ARID1 A; Epithelial ovarian cancer; HDAC6; HDAC6 inhibitor immunotherapy; SWI/SNF; TP53

Mesh：

Substances：

Year:  2017        PMID： 29279027      PMCID： PMC5788417          DOI： 10.1080/15384101.2017.1377503

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.

Authors:  Brooke E Howitt; Kyle C Strickland; Lynette M Sholl; Scott Rodig; Lauren L Ritterhouse; Dipanjan Chowdhury; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

Review 2.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

3.  ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

Authors:  Bin Guan; Tian-Li Wang; Ie-Ming Shih
Journal:  Cancer Res       Date:  2011-09-07       Impact factor: 12.701

4.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

5.  ARID1A mutations in endometriosis-associated ovarian carcinomas.

Authors:  Kimberly C Wiegand; Sohrab P Shah; Osama M Al-Agha; Yongjun Zhao; Kane Tse; Thomas Zeng; Janine Senz; Melissa K McConechy; Michael S Anglesio; Steve E Kalloger; Winnie Yang; Alireza Heravi-Moussavi; Ryan Giuliany; Christine Chow; John Fee; Abdalnasser Zayed; Leah Prentice; Nataliya Melnyk; Gulisa Turashvili; Allen D Delaney; Jason Madore; Stephen Yip; Andrew W McPherson; Gavin Ha; Lynda Bell; Sian Fereday; Angela Tam; Laura Galletta; Patricia N Tonin; Diane Provencher; Dianne Miller; Steven J M Jones; Richard A Moore; Gregg B Morin; Arusha Oloumi; Niki Boyd; Samuel A Aparicio; Ie-Ming Shih; Anne-Marie Mes-Masson; David D Bowtell; Martin Hirst; Blake Gilks; Marco A Marra; David G Huntsman
Journal:  N Engl J Med       Date:  2010-09-08       Impact factor: 91.245

6.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.

Authors:  Benjamin G Bitler; Katherine M Aird; Azat Garipov; Hua Li; Michael Amatangelo; Andrew V Kossenkov; David C Schultz; Qin Liu; Ie-Ming Shih; Jose R Conejo-Garcia; David W Speicher; Rugang Zhang
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

7.  ARID1A-mutated ovarian cancers depend on HDAC6 activity.

Authors:  Benjamin G Bitler; Shuai Wu; Pyoung Hwa Park; Yang Hai; Katherine M Aird; Yemin Wang; Yali Zhai; Andrew V Kossenkov; Ana Vara-Ailor; Frank J Rauscher; Weiping Zou; David W Speicher; David G Huntsman; Jose R Conejo-Garcia; Kathleen R Cho; David W Christianson; Rugang Zhang
Journal:  Nat Cell Biol       Date:  2017-07-24       Impact factor: 28.824
  7 in total
  1 in total

1.  Single-PanIN-seq unveils that ARID1A deficiency promotes pancreatic tumorigenesis by attenuating KRAS-induced senescence.

Authors:  Shou Liu; Wenjian Cao; Yichi Niu; Jiayi Luo; Yanhua Zhao; Zhiying Hu; Chenghang Zong
Journal:  Elife       Date:  2021-05-13       Impact factor: 8.140
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.